2022 World Conference on Lung Cancer (ePosters)-EP08.02-060. How Do Oncologists Treat Patients With EGFR Exon-20 Mutant NSCLC Outside of Clinical Trials? Updated Analysis From the European EXOTIC Registry

EP08.02-060. How Do Oncologists Treat Patients With EGFR Exon-20 Mutant NSCLC Outside of Clinical Trials? Updated Analysis From the European EXOTIC Registry

Back to course

Pdf Summary

The European EXOTIC registry conducted a final analysis on the treatment of patients with EGFR exon-20 mutant non-small cell lung cancer (NSCLC) outside of clinical trials. The registry collected clinical, pathological, and molecular epidemiology data from 175 patients diagnosed between January 2019 and December 2021. The main features of the patients included a median age of 64 years, predominantly female (56%), and never/past smokers (76%). Adenocarcinoma was the most common type of NSCLC (95.4%), with a high incidence of bone (47.4%) and brain (32%) metastases.<br /><br />The treatment patterns recorded in the registry included chemotherapy, chemotherapy with immunotherapy, osimertinib, poziotinib, mobocertinib, mono-immunotherapy, and amivantamab. The disease control rates varied among the different treatment options, with chemotherapy and chemotherapy with immunotherapy achieving a 66.2% and 55.8% disease control rate, respectively. Osimertinib, poziotinib, and mobocertinib had disease control rates of 64.8%, 76.9%, and 64.8%, respectively. The corresponding median survival ranged from 9.2 to 22.4 months.<br /><br />The analysis also revealed that the type of treatment, specifically the use of new targeted agents compared to chemotherapy or chemotherapy with immunotherapy, had an impact on progression-free survival and overall survival. In multivariate analysis, poziotinib showed a statistically significant improvement in both progression-free survival and overall survival compared to chemotherapy.<br /><br />The EXOTIC registry represents the largest real-world evidence dataset on EGFR exon-20 mutant NSCLC in Europe. The findings suggest that chemotherapy, chemotherapy with immunotherapy, and newer targeted agents through early access programs are the mainstays of first-line treatment for these patients. Further research is needed to validate these results and explore additional treatment options for EGFR exon-20 mutant NSCLC patients.

Asset Subtitle

Giannis Mountzios

Meta Tag

Speaker Giannis Mountzios

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

EGFR exon-20 mutant

NSCLC

treatment

chemotherapy

immunotherapy

osimertinib

poziotinib

mobocertinib

survival

progression-free survival